Cited by 218Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Amyloid burden and neural function in people at risk for Alzheimer's Disease

Open access
Johnson, Sterling C., Christian, Bradley T., Okonkwo, Ozioma C., Oh, Jennifer M., Harding, Sandra, Xu, Guofan, Hillmer, Ansel T., Wooten, Dustin W. +14 more·2014·Neurobiology of Aging

Abstract

To determine the relationship between amyloid burden and neural function in healthy adults at risk for Alzheimer's Disease (AD), we used multimodal imaging with [C-11]Pittsburgh compound B positron emission tomography, [F-18]fluorodeoxyglucose, positron emission tomography , and magnetic resonance imaging, together with cognitive measurement in 201 subjects (mean age, 60.1 years; range, 46-73 years) from the Wisconsin Registry for Alzheimer's Prevention. Using a qualitative rating, 18% of the samples were strongly positive Beta-amyloid (Aβ+), 41% indeterminate (Aβi), and 41% negative (Aβ-). Aβ+ was associated with older age, female sex, and showed trends for maternal family history of AD and APOE4. Relative to the Aβ- group, Aβ+ and Aβi participants had increased glucose metabolism in the bilateral thalamus; Aβ+ participants also had increased metabolism in the bilateral superior temporal gyrus. Aβ+ participants exhibited increased gray matter in the lateral parietal lobe bilaterally relative to the Aβ- group, and no areas of significant atrophy. Cognitive performance and self report cognitive and affective symptoms did not differ between groups. Amyloid burden can be identified in adults at a mean age of 60 years and is accompanied by glucometabolic increases in specific areas, but not atrophy or cognitive loss. This asymptomatic stage may be an opportune window for intervention to prevent progression to symptomatic AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2013.09.028

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased thalamic volume and hypermetabolism with amyloid pathology have been reported among APOE4 carriers.

    “The role of thalamic structure and function in AD appears complex and perhaps nonlinear, as thalamic atrophy in MCI [48] and hypometabolism in APOE4 carriers [49] have been observed, whereas others have reported increased thalamic volume [50] and hypermetabolism with amyloid pathology [51] among APOE4 carriers.”

    From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [51]

    Results §3.3 reports greater medial-thalamic glucose metabolism in participants with indeterminate or positive amyloid burden than in amyloid-negative participants. The cohort was enriched for APOE4 carriers, but the analysis grouped participants by amyloid burden, not carrier status; the Discussion also reports no significant APOE-genotype association. The separate increased-volume finding is attributed to citation [50], not this paper. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Johnson, S. C., Christian, B. T., Okonkwo, O. C., Oh, J. M., Harding, S., Xu, G., Hillmer, A. T., Wooten, D. W., Murali, D., Barnhart, T. E., Hall, L. T., Racine, A. M., Klunk, W. E., Mathis, C. A., Bendlin, B. B., Gallagher, C. L., Carlsson, C. M., Rowley, H. A., Hermann, B. P., Dowling, N. M., Asthana, S., & Sager, M. A.
Affiliations
  • University of Wisconsin–Madison (US)
  • University of Pittsburgh (US)
Corresponding author
Johnson, Sterling C.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2014-03
Volume
35
Issue
3
Pages
576-584
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2054509396
Cited by
218
References
64
Citations by year
2026: 11 · 2025: 28 · 2024: 23 · 2023: 16 · 2022: 20 · 2021: 23 · 2020: 14 · 2019: 16 · 2018: 11 · 2017: 12 · 2016: 13 · 2015: 13 · 2014: 18
FWCI
10.38
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIA (AG021155, AG027161, P50 AG033514)
  • Veterans Administration Merit Review (I01CX000165, P50 HD03352)
  • Helen Bader Foundation
  • Northwestern Mutual Foundation
  • Extendicare Foundation
  • Geriatric Research Education
  • Clinical Center of the William S. Middleton Memorial Veterans Hospital
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
amyloid burden, amyloid-beta, Alzheimer's disease risk, superior temporal gyrus, gray matter volume, APOE ε4, family history of Alzheimer's disease, cognitive performance, Wisconsin Registry for Alzheimer's Prevention, amyloid imaging
MeSH terms
Aged, Alzheimer Disease, Brain, Cognition, Female, Glucose, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Registries, Risk Factors, Cohort Studies, Amyloid beta-Peptides, Disease Progression, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review